The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy

BACKGROUND: IRAK1 has been shown to be abnormally expressed in a set of tumors leading to tumorigenesis and progression. IRAK1 is a therapeutic target that drives breast cancer metastasis and resistance to paclitaxel. However, the exact role of IRAK1 in neoadjuvant chemotherapy (NCT) for breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Muwen, Qin, Xingsong, Qin, Guangyuan, Zheng, Xinyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438138/
https://www.ncbi.nlm.nih.gov/pubmed/30988621
http://dx.doi.org/10.2147/OTT.S185662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6438138/
https://www.ncbi.nlm.nih.gov/pubmed/30988621
http://dx.doi.org/10.2147/OTT.S185662

Ejemplares similares